2426 related articles for article (PubMed ID: 23884809)
1. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
[TBL] [Abstract][Full Text] [Related]
2. Severe nigrostriatal degeneration without clinical parkinsonism in patients with polymerase gamma mutations.
Tzoulis C; Tran GT; Schwarzlmüller T; Specht K; Haugarvoll K; Balafkan N; Lilleng PK; Miletic H; Biermann M; Bindoff LA
Brain; 2013 Aug; 136(Pt 8):2393-404. PubMed ID: 23625061
[TBL] [Abstract][Full Text] [Related]
3. Detrimental deletions: mitochondria, aging and Parkinson's disease.
Biskup S; Moore DJ
Bioessays; 2006 Oct; 28(10):963-7. PubMed ID: 16998822
[TBL] [Abstract][Full Text] [Related]
4. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
5. Catecholamine metabolism drives generation of mitochondrial DNA deletions in dopaminergic neurons.
Neuhaus JF; Baris OR; Hess S; Moser N; Schröder H; Chinta SJ; Andersen JK; Kloppenburg P; Wiesner RJ
Brain; 2014 Feb; 137(Pt 2):354-65. PubMed ID: 24163249
[TBL] [Abstract][Full Text] [Related]
6. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
Hill WD; Arai M; Cohen JA; Trojanowski JQ
J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
[TBL] [Abstract][Full Text] [Related]
7. LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
Sloan M; Alegre-Abarrategui J; Potgieter D; Kaufmann AK; Exley R; Deltheil T; Threlfell S; Connor-Robson N; Brimblecombe K; Wallings R; Cioroch M; Bannerman DM; Bolam JP; Magill PJ; Cragg SJ; Dodson PD; Wade-Martins R
Hum Mol Genet; 2016 Mar; 25(5):951-63. PubMed ID: 26744332
[TBL] [Abstract][Full Text] [Related]
8. Neuronal vulnerability in Parkinson's disease.
Double KL
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S52-4. PubMed ID: 22166454
[TBL] [Abstract][Full Text] [Related]
9. The Absence of Parkin Does Not Promote Dopamine or Mitochondrial Dysfunction in PolgA
Scott L; Karuppagounder SS; Neifert S; Kang BG; Wang H; Dawson VL; Dawson TM
J Neurosci; 2022 Dec; 42(49):9263-9277. PubMed ID: 36280265
[TBL] [Abstract][Full Text] [Related]
10. Mesencephalic complex I deficiency does not correlate with parkinsonism in mitochondrial DNA maintenance disorders.
Palin EJ; Paetau A; Suomalainen A
Brain; 2013 Aug; 136(Pt 8):2379-92. PubMed ID: 23811324
[TBL] [Abstract][Full Text] [Related]
11. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.
Kordower JH; Olanow CW; Dodiya HB; Chu Y; Beach TG; Adler CH; Halliday GM; Bartus RT
Brain; 2013 Aug; 136(Pt 8):2419-31. PubMed ID: 23884810
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia.
Allen AM; MacGregor DP; Chai SY; Donnan GA; Kaczmarczyk S; Richardson K; Kalnins R; Ireton J; Mendelsohn FA
Ann Neurol; 1992 Sep; 32(3):339-44. PubMed ID: 1416803
[TBL] [Abstract][Full Text] [Related]
13. Parkin deficiency accelerates consequences of mitochondrial DNA deletions and Parkinsonism.
Song L; McMackin M; Nguyen A; Cortopassi G
Neurobiol Dis; 2017 Apr; 100():30-38. PubMed ID: 28042097
[TBL] [Abstract][Full Text] [Related]
14. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system.
Hunter RL; Dragicevic N; Seifert K; Choi DY; Liu M; Kim HC; Cass WA; Sullivan PG; Bing G
J Neurochem; 2007 Mar; 100(5):1375-86. PubMed ID: 17254027
[TBL] [Abstract][Full Text] [Related]
15. Protective effects of Chunghyuldan against ROS-mediated neuronal cell death in models of Parkinson's disease.
Kim HG; Ju MS; Kim DH; Hong J; Cho SH; Cho KH; Park W; Lee EH; Kim SY; Oh MS
Basic Clin Pharmacol Toxicol; 2010 Dec; 107(6):958-64. PubMed ID: 20629656
[TBL] [Abstract][Full Text] [Related]
16. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
[TBL] [Abstract][Full Text] [Related]
17. Native DIGE proteomic analysis of mitochondria from substantia nigra and striatum during neuronal degeneration and its compensation in an animal model of early Parkinson's disease.
Kuter K; Kratochwil M; Marx SH; Hartwig S; Lehr S; Sugawa MD; Dencher NA
Arch Physiol Biochem; 2016 Dec; 122(5):238-256. PubMed ID: 27467289
[TBL] [Abstract][Full Text] [Related]
18. Pathological changes in dendrites of substantia nigra neurons in Parkinson's disease: a Golgi study.
Patt S; Gertz HJ; Gerhard L; Cervós-Navarro J
Histol Histopathol; 1991 Jul; 6(3):373-80. PubMed ID: 1725760
[TBL] [Abstract][Full Text] [Related]
19. Conditional deletion of Ndufs4 in dopaminergic neurons promotes Parkinson's disease-like non-motor symptoms without loss of dopamine neurons.
Choi WS; Kim HW; Tronche F; Palmiter RD; Storm DR; Xia Z
Sci Rep; 2017 Mar; 7():44989. PubMed ID: 28327638
[TBL] [Abstract][Full Text] [Related]
20. Mutant Twinkle increases dopaminergic neurodegeneration, mtDNA deletions and modulates Parkin expression.
Song L; Shan Y; Lloyd KC; Cortopassi GA
Hum Mol Genet; 2012 Dec; 21(23):5147-58. PubMed ID: 22949510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
